Skip to main content

Table 4 Clinical evidence for adoptive transfer of multivirus-specific T cells

From: Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation

Reference Method No. of patients Results Dose
In vitro stimulation and expansion
Leen et al. (2006) [40] Allogeneic CMV-, EBV, and AdV-specific CD8+ T cells 11 All patients eliminated the viral pathogen 5 × 106–1 × 108 cells/m2
Leen et al. (2009) [54] Allogeneic EBV- and AdV-specific CD8+ T cells 13 Therapy: 2/2 AdV clearance prophylaxis: 13/13 no PTLD 0.5–13.5 × 107 cells/m2
Gerdemann et al. (2013) [68] Allogeneic CMV-, EBV, and AdV- specific CD8+ T cells phase I/II 10 (infections: 3 CMV, 1 AdV, 2 EBV, 2 EBV + AdV, 2 CMV + AdV) 8/10 complete responses 5 × 106–2 × 107 cells/m2
Withers et al. (2017 and 2018) [55, 59] Third-party CD8+ and CD4+ CMV-, EBV, AdV, and varicella-zoster virus-specific T cells phase I 1 1/1 responded 3 infusions of 1.37–5 × 107 cells/m2
Direct isolation via cytokine-capture technique
Kàllay et al. (2018) [43] CMV- and EBV-specific or CMV- and AdV-specific CD8+ and CD4+ T cells 3 (infections: 2 CMV + AdV, 1 CMV + EBV) 3/3 responders 3.2–4.8 × 104 cells/kg